Hims & Hers Health (NYSE:HIMS) Stock Price Down 5% After Analyst Downgrade

Hims & Hers Health, Inc. (NYSE:HIMS) traded down 5% on Tuesday after Truist Financial lowered their price target on the stock from $48.00 to $37.00. Truist Financial currently has a hold rating on the stock. Hims & Hers Health traded as low as $43.21 and last traded at $42.84. 6,014,452 shares were traded during trading, a decline of 82% from the average session volume of 33,741,582 shares. The stock had previously closed at $45.10.

A number of other brokerages have also recently commented on HIMS. Morgan Stanley reiterated an “equal weight” rating and issued a $40.00 target price on shares of Hims & Hers Health in a research report on Wednesday, June 11th. Wall Street Zen cut Hims & Hers Health from a “buy” rating to a “hold” rating in a research note on Monday, July 28th. Piper Sandler reissued a “neutral” rating and issued a $39.00 target price (up previously from $35.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Bank of America increased their target price on Hims & Hers Health from $22.00 to $26.00 and gave the company an “underperform” rating in a report on Tuesday, April 29th. Finally, TD Cowen cut Hims & Hers Health from a “buy” rating to a “hold” rating and decreased their price target for the stock from $44.00 to $30.00 in a research note on Tuesday, April 29th. Two investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Reduce” and a consensus price target of $38.92.

Insider Activity at Hims & Hers Health

In related news, CEO Andrew Dudum sold 660,000 shares of the stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $50.58, for a total value of $33,382,800.00. Following the completion of the transaction, the chief executive officer directly owned 2,214,769 shares of the company’s stock, valued at $112,023,016.02. This represents a 22.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Patrick Harrison Carroll sold 60,000 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $53.58, for a total value of $3,214,800.00. Following the sale, the insider directly owned 169,940 shares in the company, valued at approximately $9,105,385.20. The trade was a 26.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,267,963 shares of company stock worth $66,154,224 over the last ninety days. Corporate insiders own 13.71% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Signaturefd LLC raised its holdings in Hims & Hers Health by 17.7% in the first quarter. Signaturefd LLC now owns 2,586 shares of the company’s stock worth $76,000 after buying an additional 388 shares during the last quarter. GAMMA Investing LLC raised its position in Hims & Hers Health by 128.5% in the 1st quarter. GAMMA Investing LLC now owns 5,143 shares of the company’s stock worth $152,000 after buying an additional 2,892 shares during the last quarter. New York State Teachers Retirement System raised its position in Hims & Hers Health by 95.2% in the 1st quarter. New York State Teachers Retirement System now owns 194,795 shares of the company’s stock worth $5,756,000 after buying an additional 94,983 shares during the last quarter. BNP Paribas Financial Markets bought a new position in Hims & Hers Health during the 4th quarter valued at about $1,230,000. Finally, Fifth Third Bancorp lifted its stake in Hims & Hers Health by 165.4% during the 1st quarter. Fifth Third Bancorp now owns 1,542 shares of the company’s stock valued at $46,000 after acquiring an additional 961 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Stock Performance

The business’s fifty day moving average price is $52.18 and its 200-day moving average price is $45.73. The stock has a market cap of $9.83 billion, a PE ratio of 54.34, a P/E/G ratio of 2.85 and a beta of 2.08. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The company had revenue of $544.83 million for the quarter, compared to analysts’ expectations of $550.06 million. During the same period in the previous year, the firm earned $0.06 earnings per share. The firm’s revenue for the quarter was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.